Introduction {#Sec1}
============

Graft-versus-host disease (GVHD) is the main cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (HSCT). Despite the use of standard prophylaxis 35--50% and 35--70% of HSCT recipients will develop acute (aGVHD) \[[@CR1]\] and chronic GVHD (cGVHD) \[[@CR2]\], respectively.

First-line systemic treatment consists of high doses of corticosteroids. Unfortunately, more than 50% of the patients will not respond adequately, thus requiring second-line treatment \[[@CR3]\]. This subgroup of patients has an especially poor prognosis, with a significantly higher risk of treatment-related mortality \[[@CR4]\]. Until recently, there were no approved therapies for GVHD treatment \[[@CR5]\].

Ruxolitinib is an orally administered selective Janus Kinase (JAK) inhibitor approved for the treatment of myelofibrosis and polycythemia vera \[[@CR6]--[@CR9]\]. JAK inhibitors relieve symptoms related to an excess of proinflammatory cytokines in these patients \[[@CR10], [@CR11]\]. Due to the key role of JAK-STAT pathways on T cells activation, JAK inhibitors may reduce GVHD by inhibiting donor T-cell expansion and inflammatory cytokine production, regulatory T-cell (Treg) function and viability. Based on this background, Spoerl et al. \[[@CR12]\] and Zeiser et al. \[[@CR13]\] have reported the effectiveness of ruxolitinib to control GVHD in both mice and humans.

Several approaches have been evaluated as recue therapy within the second-line treatment. The difficulty in grading the severity (consequence of the high heterogeneity of the manifestations) and the treatment responses, as well as the sequential or concomitant treatment with several immunosuppressive drugs, makes it difficult to evaluate the effectiveness of any approach. In this context, the German group \[[@CR13]\] has published data from a retrospective study in which 95 patients with moderate-severe GVHD refractory to steroids were treated with ruxolitinib. The overall response rates (ORR) were 44/54 (81%) and 35/41 (85%) for aGVHD and cGVHD respectively, with rates of up to 46% of complete responses (CR) in aGVHD. To assess long-term follow-up results, they collected data in a second analysis \[[@CR14]\] from the same patients. Ongoing ORR was 22/54 (41%) and 10/41 (24%) after a median follow-up of 19 and 24 months for aGVHD and cGVHD groups. The 1-year overall survival (OS) was 62.4% (CI: 49.4--75.4%) and 92.7% (CI: 84.7--100%), respectively. Other authors, such as Khoury et al. \[[@CR15]\], reported the outcomes of 19 patients with cGVHD who received salvage therapy with ruxolitinib. They described early partial responses (PR) in 18 out of 19 patients as well as a sustained steroid-sparing effect in 17 out of 19 patients.

On May 24, 2019, the Food and Drug Administration approved ruxolitinib (JAKAFI, Incyte Corporation) for steroid-refractory aGVHD in adult and pediatric patients 12 years and older \[[@CR5]\]. Approval was based on Study INCB 18424-271 (NCT02953678), an open-label, single-arm, multicenter study of ruxolitinib that enrolled 49 patients with steroid-refractory aGVHD grades 2--4 (Mount Sinai Acute GVHD International Consortium criteria). Ruxolitinib was administered at 5 mg twice daily, and the dose could be increased to 10 mg twice daily. The trial's primary endpoints were day-28 ORR. The median response duration was 16 days (95% CI: 9, 83), and the median time from day-28 response to either death or need for new therapy for aGVHD was 173 days (95% CI 66, NE).

In addition, Novartis Inc is running two large phase III trials of ruxolitinib vs best standard of care in steroid-refractory aGVHD and cGVHD. They are open-label studies in period of recruiting. However clinical data and outcomes are not available yet.

With this background, we analyzed the use of ruxolitinib in the treatment of GVHD within the Spanish Group of Hematopoietic Transplant and Cell Therapy (GETH) centers. Our data add evidence to the information available so far, on this new therapeutic strategy.

Methods {#Sec2}
=======

Study population {#Sec3}
----------------

Between October 2015 to July 2017, 79 patients who underwent an HSCT and developed GVHD resistant to steroids received ruxolitinib. They were evaluated in this retrospective, observational, and multicenter study using data collected from 13 Spanish centers, including seven pediatric patients (\<14 years). Off-label treatment with ruxolitinib and data analysis were approved by the Clinical Research Ethics Committee of the Hospital Universitario Ramón y Cajal, Spain.

The median age was 51 years (range, 0--73). The most frequent underlying diseases were: acute myeloid leukemia (38%), non-Hodgkin lymphoma (16.5%) and acute lymphoblastic leukemia (15.2%). The majority of patients received reduced-intensity conditioning regimens (57%). Patient baseline characteristics of the entire population are shown in Table [1](#Tab1){ref-type="table"}. Of note, 53% and 55% of patients with aGVHD or cGVHD, respectively, have received three or more lines or prior therapy.Table 1Patient characteristics*N* (%)Gender Male48 (60.8) Female31 (39.2)Age Median (range)51 (0--73)Underlying disease Acute myeloblastic leukemia30 (38) Acute lymphoblastic leukemia12 (15.2) Myelodysplastic syndrome11 (13.9) Multiple myeloma3 (3.8) Hodgkin disease2 (2.5) Non-Hodgkin disease13 (16.5) Myelofibrosis4 (5.1) Others4 (5.1)Disease status previous HSCT CR47 (59.5) PR13 (16.5) SD11 (13.9) Others8 (10,1)Type of transplant Related HLA identical donor33 (41.7) Haploidentical7 (8.8) Unrelated donor39 (49.3)Conditioning regimen Myeloablative34 (43) Reduced-intensity45 (57)Source Peripheral blood75 (95) Bone marrow2 (2.5) Umbilical cord2 (2.5)Acute GVHD (*n* = 23)*N* (%)Grades 2--423 (100) 3--420 (87)Organs involved Skin16 (69.6) Gut21 (95.5) Liver13 (59.1)Previous lines of therapy 14 (18.2) 27 (31.8) 36 (26.1) \>36 (27.2)Chronic GVHD (*n* = 56)*N* (%)NIH score Mild0 (0) Moderate28 (50) Severe28 (50)Organs involved Skin44 (78.5) Sclerotic changes25 (41.1) Resembling lichen planus2 (3.6) Rash13 (23.2) Hyper/hypopigmentation3 (5.4) Ichthyosis3 (5.4) Oral33 (58.9) Ocular23 (41) Gut16 (28.6) Liver10 (17.8) Lung26 (45) Joint mobility disfunction22 (39.4) Urinary tract7 (12.5) Esophageal membrane2 (3.6) Pericardial/pleural effusion2 (3.6) Nephrotic syndrome1 (1.8) Neuropathy1 (1.8) Microangiopathy1 (1.8) Polymyositis3 (5.3)Previous lines of therapy 14 (7.1) 220 (35.7) 311 (19.6) \>321 (37.6)

The study was carried out in accordance with the principles of Declaration of Helsinki and received approval by an independent Clinical Research Ethics Committee. Written informed consent for collection data was obtained and signed from each patient after being treated with ruxolitinib. Confidentiality of data collection was preserved following local regulations (Organic Law 15/1999 of December 13, Protection of Personal Data \[LOPD\]). Likewise, Law 14/2007 on Biomedical Research was respected.

Inclusion criteria and treatment plan {#Sec4}
-------------------------------------

Patients undergoing HSCT in GETH centers with steroid-refractory GVHD treated with ruxolitinib were included in the analysis. Refractoriness of aGVHD was defined as "progression within 3--5 days of starting treatment or an incomplete response by 7--14 days. Refractory cGVHD was defined as "cGVHD of sustained severity during the last full month during which the patients had received the equivalent of prednisone 0.5 mg/kg or more per day or 1 mg/kg or more every other day".

The severity of the disease was evaluated according to the International Bone Marrow Transplant Registry criteria for aGVHD \[[@CR16]\] and according to the international consensus of National Institutes of Health (NIH) for cGVHD \[[@CR17]\]. Patients were scored for their best response at any time after starting ruxolitinib. Treatment responses were considered when patients achieved CR or PR. Other types of responses were considered treatment failure.

Regarding aGVHD, CR was defined as the absence of symptoms related to the GVHD. The PR as improvement of at least one category of the severity of aGVHD in one organ without deterioration in any other. Treatment failure was defined as the lack of improvement of GVHD, deterioration in any organ, appearance of new symptomatology associated with GVHD or the need to start a new treatment for the control of the disease.

Regarding cGVHD, response assessment was performed following NIH criteria \[[@CR18]\]. CR was defined as resolution of all manifestations related to cGVHD in a specific organ; PR as improvement in score from baseline reflecting genuine clinical benefit; and treatment failure as criteria for progression defined in NIH consensus. Discontinuation of ruxolitinib due to toxicity was not considered treatment failure. Histologic GVHD grading was performed on the basis of histopathology according to a published staging system for histology and clinical grading according to criteria for aGVHD or cGVHD \[[@CR19]\].

Study design {#Sec5}
------------

This is a retrospective, observational and multicenter study. Safety and efficacy data were analyzed in patients who have already been treated with ruxolitinib in the clinical practice under a compassionate use. The study did not imply a change in the therapeutic action or additional tests. The information source was patient´s clinical history in all cases. The study was performed within the hospital setting, with the participation of Departments of Hematology belonging to the Spanish Group of Hematopoietic Transplant and Cell Therapy (GETH) distributed throughout the national territory. Data were collected in a specific Electronic Case Report Form especially designed for the study.

Statistics {#Sec6}
----------

Results were analyzed using the Statistical Package for the Social Sciences (SPSS PASW18). A *p* \< 0.05 was considered statistically significant. OS was calculated in our study at one year with Stata/IC 15.0 program. Given that the objective of the study was merely descriptive, and therefore, there was not hypothesis to be confirmed, the sample estimation prior to the study was not necessary.

Results {#Sec7}
=======

Ruxolitinib in aGVHD {#Sec8}
--------------------

Twenty-three patients received ruxolitinib for refractory aGVHD. All patients had grades 2--4 aGVHD and 20 patients (87%) had grades 3--4; the median number of previous lines of therapy was 3 (range 1--5). ORR was 69.5% (16/23) which was obtained after a median of 2 weeks of treatment (range: 0.5--4 weeks), and 21.7% (5/23) reached CR. Median follow-up was 78 days (range: 4--913). The median dose of ruxolitinib was 20 mg/day divided in two doses. Remarkably, we found no differences in treatment responses depending on the organs involved (Table [2](#Tab2){ref-type="table"}). More specifically, 66.7% of patients with gastrointestinal GVHD did respond, 19% obtaining CR. The use of ruxolitinib allowed to taper steroids doses in 17/23 of patients (73.7%). Globally, overall survival at 6 months was 47% (CI: 23--67%) (Fig. [1a](#Fig1){ref-type="fig"}). Overall survival (OS) at 6 months in responders vs non-responders was 62% vs 28%, respectively (Fig. [1b](#Fig1){ref-type="fig"}).Table 2Ruxolitinib responsesAcute GVHD (*n* = 23)ORRCRROverall response16/23 (69.5)5/23 (21.7)Response rate in grades 3--414/20 (70)5/20 (25)RR by organs Skin11/16 (68.8)3/16 (18.7) Gut14/21 (66.7)4/21 (19) Liver9/13 (69.2)3/13 (23)RR ≥ 3 lines of treatment9/12 (75) And aGVHV grades 3--48/11 (72.7)2/11 (18.2) And skin involvement8/10 (80)2/9 (20) And gut involvement8/11 (72.7)1/11 (9) And liver involvement4/6 (66.7)1/6 (16)Chronic GVHD (*n* = 56)ORRCRROverall response32/56 (57.1)2/56 (3.5)RR by grades Moderate17/28 (60.7)1/28 (3.5) Severe15/28 (53.5)1/28 (3.5)RR by organs Skin with sclerotic changes14/25 (56)0/25 (0) Lung16/26 (61.5)2/26 (7) Gut9/16 (56.3)2/16 (12)RR ≥3 lines of treatment17/32 (53.1)2/32 (6.3) And moderate plus severe17/32 (53.1)2/32 (6.3) cGVHD And skin involvement with sclerotic changes8/15 (53.3)0/15 (0) And lung involvement10/14 (71.4)2/14 (14.2) And gut involvement7/10 (70)2/10 (20)Fig. 1**a** Overall survival among patients with acute GVHD. **b** Overall survival in responders vs non-responder acute GVHD patients

Ruxolitinib in cGVHD {#Sec9}
--------------------

Fifty-six patients were evaluated for refractory cGVHD. All patients had moderate (28/57, 50%) to severe (28/57, 50%) cGVHD. The median number of previous lines of therapy was 3 (range 1--10). ORR was 57.1% (32/56) with 3.5% (2/56) obtaining CR which was obtained at a median of 4 weeks of treatment (range: 1--24 weeks). Median follow-up was 181 days (range: 15--560). The median dose administrated was 20 mg daily divided in two doses. Again, no differences were found upon analyzing response rate by organs involved. Remarkably, ORR in patients with sclerotic changes was 56%, for those with lung involvement 61.5% and for those with gut involvement 56.3%. Responses for lung involvement were evaluated according to NIH scoring/staging/response assessment as part of standard clinical practice. Thirty-two patients (59.2%) could taper the doses of steroids. OS at 1 year was 81% (IC: 63--89) (Fig. [2a](#Fig2){ref-type="fig"}). OS at 1 year in responders vs non-responders was 83% vs 76%, respectively (Fig. [2b](#Fig2){ref-type="fig"}).Fig. 2**a** Overall survival among patients with chronic GVHD. **b** Overall survival in responders vs non-responder chronic GVHD patients

Toxicities, relapse, and mortality {#Sec10}
----------------------------------

Cytomegalovirus (CMV) reactivation was observed both in aGVHD and chronic subgroups of patients while on treatment with ruxolitinib. Regarding aGVHD, CMV reactivation occurred in 12/23 (52.2%) patients, while in the cGVHD subgroup, it was observed in 11/56 (19.6%) patients. Nevertheless, when we analyzed CMV reactivation before ruxolitinib treatment was started, the incidence was similar or even higher: among patients with aGVHD: 12/23 (52.2%); and among patients with cGHVD: 15/56 (26%), indicating that ruxolitinib may not exert a significant increase in the risk of CMV reactivation. Monitoring by plasma CMV PCR was performed in all recipients and CMV reactivations were treated according to clinical practice. Since these data were retrospectively collected in different centers, there was not a uniform algorithm. Globally, it was defined as 2 confirmed PCR CMV tested above 600 copies. Those patients with confirmed reactivation received valgancyclovir (foscarnet in case of severy neutropenia) according to current recommendations.

Overall, 26 patients (32.9%) interrupted ruxolitinib due to: lack of response (14), cytopenias (three patients had thrombocytopenia, three anemia, three had both); infections (1); and other causes (2).

Regarding drug-related toxicities, only three patients discontinued ruxolitinib (Table [3](#Tab3){ref-type="table"}). Causes for discontinuation in these patients were fungal infection, thrombocytopenia, and hepatic impairment. For 16 patients, it was sufficient with temporary suspension or dose reduction.Table 3Toxicities, adverse events, and malignancy relapseToxicities and adverse events*N* = 26/79 (32.9%)Infections4 (5) Fungal infection2 Bacterial/viral infection2Cytopenia14 (17.7) Anemia3 Leukopenia2 Thrombocytopenia5 Combinations4Others8 (10.1) Renal impairment3 Hepatic impairment3 Hypertension1 Edema1Action Dose reduction14 (17.7) Temporary suspension2 (2.5) Discontinuation3 (3.7) No actions/Others7 (8.8)Malignancy relapse1 (1.2)

Relapse of the underlying malignancy was only observed in one non ruxolitinib-responsive patient.

Globally, 18 patients (22.8%) died: 10/23 patients (43.5%) within the aGVHD and 8/56 patients (14.3%) within the cGVHD subgroup. Causes of death were: infections (10), refractory GVHD (6) and other causes (2).

We also analyzed bilirubin, alkaline phosphatase, creatinine and LHD levels before ruxolitinib was started. However, we did not find any biomarkers that could predict treatment responses. Median bilirubin, alkaline phosphatase, creatinine, and LHD levels were 1.5 mg, 117 U/L, 1 mg/dl, and 289 U/L respectively.

Discussion {#Sec11}
==========

The development of novel approaches for the treatment of relapsed or refractory GVHD is an unmet medical need. In the current study, ORR among patients with aGVHD was 69.5% (16/23) with 21.7% (5/23) patients obtaining CR. Among patients with refractory cGVHD, ORR was 57.1% (32/56) with 3.5% (2/56) obtaining CR. It is worth mentioning that, in the current study, the response rate reached 56% for cGVHD with skin involvement and sclerotic features, which is promising considering the limited therapeutic options for these patients \[[@CR20]\]. Similarly, lung involvement is one of the most severe features of cGVHD. We observed a response rate of 61% among these patients. Other studies using extracorporeal photopheresis have observed a response rate in the range of 33--63% \[[@CR21]\]. In addition, considering that ruxolitinib is administrated orally, there might be some concerns regarding its absorption and biodistribution. Noteworthy, ORR reached 67 and 56% among patients with gastrointestinal aGVHD and cGVHD, respectively. Considering the retrospective nature of the study, we did not set a specific time point post ruxolitinib for GVHD assessment, but we based our analysis on the time of best response. The lack of a standardized time point to assess ORR is a limitation and could be considered a flaw in the methodology. Nevertheless, taking into account the median time to best response for aGVHD by day 14 and considering that late responses occurred up to day 27, our data does well represent the ORR occurring by day +28, which is currently considered the gold standard regarding the timing for aGVHD evaluation.

The German group \[[@CR13]\] has reported data from a retrospective study in which 95 patients with moderate-severe GVHD refractory to steroids were treated with ruxolitinib. The ORR were 81% (44/54) and 85% (35/41) for aGVHD and cGVHD respectively, with rates of up to 46% (25/54) of CR in aGVHD and 7.3% (3/41) in cGVHD. OS rates at 6 months were 79% and 97%, respectively. Tapering of corticosteroids was possible in both aGVHD (17/23, 73%) and cGVHD (32/56, 57.1%) groups. In the current study, the median number of prior lines of treatment was 3 (1--5) among patients with aGVHD, and 3 (1--10) for patients with cGVHD. Accordingly, the response rates previously described were obtained in heavily pretreated patients, both in the current study as well as in the study by Zeiser et al., although ORR and CR rates were higher in the German study. Ongoing prospective randomized trials are required to confirm these data, although in both studies, the response rate is remarkable as compared with other approaches \[[@CR22]--[@CR32]\] and, furthermore, the toxicity profile was manageable in this fragile population.

The study led by Khoury et al. \[[@CR15]\], reported outcomes of 19 patients with steroid-resistant cGVHD who received salvage ruxolitnib therapy. In their analysis they described early PR in 18 out of 19 patients. Of importance, they remark the reduction to physiologic doses or discontinuation of prednisone in \~90% of patients.

Recently, Incyte Corporation has announced positive results from its ongoing pivotal Phase 2 REACH1 trial for aGVHD. The study showed an ORR of 55% (*n* = 39/71) at day 28, and the best ORR at any time was 73% (*n* = 52/71), thus corroborating our findings. The most common treatment adverse events described were anemia (61%), thrombocytopenia (61%), and neutropenia (56%).

In the current study, the safety profile was satisfactory, with the most frequent side effects consisting of cytopenias and CMV reactivation. According to our data, CMV reactivation was observed in both aGVHD (52.2%) and chronic (19.6%) GVHD during the treatment. However, the analysis of CMV reactivation before starting ruxolitinib was even higher, suggesting that treatment with ruxolitinib might not increase the risk of CMV reactivation as suggested in other studies. Therefore, CMV copy numbers should be monitored as a standard procedure according to current guidelines for clinical practice in this heavily pretreated group of patients in order to administer preemptive treatment if required, not just because of an increased risk of reactivation related to the drug but because of patients characteristics.

Concerning other toxicities related to the treatment, we found cytopenias as the most frequent event. It is known that JAK--STAT pathways are essential for cytokine-mediated hematopoiesis \[[@CR12]\]; that is the reason why thrombocytopenia and anemia are one of the major adverse effects of ruxolitinib that have been observed in other studies in myelofibrosis. In our study, only three patients discontinued ruxolitinib due to drug-related toxicities, indicating that the drug shows an excellent toxicity profile.

It is also worth mentioning that a higher immuno-suppression might lead to a potential increased risk of relapse of the underlying malignancy \[[@CR33]\]. In our study, we did not observe any relapse among ruxolitinib-responsive patients. The only relapse observed in our series was seen in a patient who did not respond to ruxolitinib. Overall, the frequency of relapse was very low (1.2%) in comparison with other studies using other immunosuppressive drugs.

In summary, ruxolitinib in the real life setting has been shown as an effective and safe treatment option for GVHD patients, with an ORR of 69.5% and 57.1% for refractory aGVHD and cGVHD, respectively, among heavily pretreated patients. It is therefore a reasonable alternative to consider for the treatment of steroid-refractory aGVHD and cGVHD. Its effectiveness has been shown both in the improvement of GVHD as well as in the probability to spare the doses of steroids.

This study has been carried out within the Grupo Español de Trasplante Hematopoyético y Terapia Celular (GETH).
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